Thomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.
Charles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.
Artificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.
Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.
Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
The Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.
Michael T. Tees, MD, discusses chimeric antigen receptor T-cell therapies, including ALLO-501A, and its use for patients with relapsed or refractory large B-cell lymphoma.
Prerna Mewawalla, MD, a hematologist at Allegheny Health Network, discusses how her approaches to patients with newly diagnosed multiple myeloma have changed recently based on clinical trial outcomes.
William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
Mehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.
Neeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.
Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
Yuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.
"I think it’s important to know that this can change over time, what is defined as transplant eligibility, so getting the transplant center involved early can be helpful."
Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
In contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.
Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Nelson J. Chao, MD, offers closing thoughts on his treatment approach for a 35-year-old woman with chronic GVHD, and looks to the future of GVHD treatment.
Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.
Adam Cohen, MD, discusses the adverse events of concern associated with B-cell maturation antigen–targeted therapies for relapsed/refractory multiple myeloma.
Liza C. Villaruz, MD, discusses the latest areas of growth in the non–small cell lung cancer space.